Wakefulness and stimulant medications
This section covers the medicines used to treat excessive sleepiness and attention disorders: what each drug is, how it works, what it is approved for, how it is dosed, and what the evidence actually supports.
Every drug has its own page, with sub-pages on safety, dosing and interactions where the detail warrants it. All of it is reference material. None of it is a recommendation, and none of it replaces a prescriber who knows your history.
Two classes, one symptom
The drugs here split cleanly into two groups. Wakefulness-promoting agents were developed for sleep disorders and act, for the most part, indirectly. Stimulants act more forcefully on catecholamine release and were developed for attention disorders, with narcolepsy as a secondary use.
The single most useful thing to hold in mind is that the two groups differ in how hard they push the same system — and therefore in abuse liability, cardiovascular load and regulatory control.
Gentler → more forceful
Approximate placement by control status and pharmacological force. Scheduling is a regulatory judgement, not a precise measure of risk, but the ordering is informative.
| Wakefulness agents | Stimulants | |
|---|---|---|
| Developed for | Sleep disorders | Attention disorders |
| Main action | Weak reuptake inhibition, histamine and orexin signalling | Reuptake blockade, and for amphetamines, reversed transport |
| US scheduling | Schedule IV, or unscheduled | Schedule II |
| Boxed warning | None | Yes, for amphetamines and methylphenidate |
| Typical duration | Long — 10 to 15 hours | Short to medium — 4 to 12 hours by formulation |
Modafinil
Schedule IV
The most widely prescribed wakefulness agent. Approved for narcolepsy, obstructive sleep apnea and shift work disorder.
Armodafinil
Schedule IV
The isolated R-enantiomer of modafinil. Same approved uses, a different concentration profile across the day.
Solriamfetol
Schedule IV
A dopamine and norepinephrine reuptake inhibitor approved in 2019 for daytime sleepiness in narcolepsy and sleep apnea.
Pitolisant
Not scheduled
A histamine H3 antagonist and inverse agonist, approved in 2019. Treats both sleepiness and cataplexy in narcolepsy.
Sodium oxybate
Schedule III
A central nervous system depressant taken at night. The long-standing treatment for cataplexy, with restricted distribution.
Amphetamines (Adderall, Vyvanse)
Schedule II · boxed warning
The most widely prescribed wakefulness agent. Approved for narcolepsy, obstructive sleep apnea and shift work disorder.
Methylphenidate
Schedule II
The isolated R-enantiomer of modafinil. Same approved uses, a different concentration profile across the day.
Caffeine
Unscheduled
A dopamine and norepinephrine reuptake inhibitor approved in 2019 for daytime sleepiness in narcolepsy and sleep apnea.
How to use this section
Researching something you have been prescribed? Start on that drug’s main page and follow the links to safety and dosing.
Trying to understand why one drug was chosen over another? The comparisons section covers the common pairings head to head.
Sleepy, and not yet evaluated? The more useful page is probably how modafinil is prescribed, which explains what a sleep assessment involves and why finding the cause matters more than treating the symptom.